Hepatitis B News and Research

Latest Hepatitis B News and Research

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

The combination of tenofovir disoproxil fumarate and entecavir induces a high rate of viral suppression in patients with chronic hepatitis B virus infection who have failed multiple nucleos(t)ide analogue regimens, phase IIIb results indicate.

13 Apr 2016

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review.

13 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Prime boost approach can increase possibility of combined HCV and HIV vaccination

A combined vaccination against Hepatitis C virus (HCV) and HIV moved a step closer, with the results of a study presented at The International Liver Congress 2016 in Barcelona, Spain today.

13 Apr 2016

Study shows 37% of outpatient healthcare staff fail to follow hand hygiene recommendations

Despite having policies in place to prevent infections, staff at outpatient care facilities fail to follow recommendations for hand hygiene 37 percent of the time, and for safe injection practices 33 percent of the time, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

12 Apr 2016

Analysis reveals improved survivorship for acute liver failure patients

More patients hospitalized with acute liver failure - often the result of acetaminophen overdose - are surviving, including those who receive a liver transplant and those who don't, an analysis led by a UT Southwestern Medical Center researcher showed.

5 Apr 2016

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals.

26 Mar 2016

Lancet experts call for evidence-based approach to drug policy

Fifty years of drug policies aimed at restricting and criminalizing drug use and minor possession have had serious detrimental effects on the health, wellbeing and human rights of drug users and the wider public, according to a major new report by The Lancet and Johns Hopkins University in the US

25 Mar 2016

Researchers discover human equivalent DAMP protein in plants

A protein that signals tissue damage to the human immune system has a counterpart that plays a similar role in plants, report researchers at the Boyce Thompson Institute.

25 Mar 2016

DAA medication could lead to revolution in hepatitis C treatment

The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago

23 Mar 2016

Mycophenolate mofetil drug seems safe, effective in treating autoimmune hepatitis

New research indicates that mycophenolate mofetil, a drug that is usually used to prevent rejection after kidney, heart or liver transplant, seems safe and effective in treating autoimmune hepatitis (AIH), a serious chronic liver disease that mainly affects women.

22 Mar 2016

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.

17 Mar 2016

Renal risk factors for NA-treated HBV patients identified

A South Korean research team has identified several clinical and medical factors associated with renal function decline in patients with chronic hepatitis B virus infection treated with oral nucleos(t)ide analogues.

10 Mar 2016

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study.

10 Mar 2016

Resistance to prior antiviral agents impacts TDF response

Taiwanese researchers find that virological response to tenofovir disoproxil fumarate in treatment-experienced patients with chronic hepatitis B virus infection can vary depending on the nucleos(t)ide analogue the patient is resistant to.

10 Mar 2016

Novel nanoparticle technology can decipher protein structures and help access drug targets

Researchers at Karolinska Institutet, Sweden, have developed a nanoparticle technology that can be used to stabilise membrane proteins so that their structure can be studied in a lipid environment. The method, described in Nature Methods, makes it possible to access drug targets that previously could not be investigated and therefore potentially allows for the development of novel drugs, therapeutic antibodies and vaccines.

9 Mar 2016

Hepatitis B News and Research

Latest Hepatitis B News and Research

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

Dynamic HBsAg measurements predict HBV inactivity

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Hepatitis C treatment can be provided safely, effectively within community-based setting

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Prime boost approach can increase possibility of combined HCV and HIV vaccination

Study shows 37% of outpatient healthcare staff fail to follow hand hygiene recommendations

Analysis reveals improved survivorship for acute liver failure patients

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Lancet experts call for evidence-based approach to drug policy

Researchers discover human equivalent DAMP protein in plants

DAA medication could lead to revolution in hepatitis C treatment

Mycophenolate mofetil drug seems safe, effective in treating autoimmune hepatitis

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Renal risk factors for NA-treated HBV patients identified

Real-world data confirm TDF efficacy for HBV

Resistance to prior antiviral agents impacts TDF response

Novel nanoparticle technology can decipher protein structures and help access drug targets

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in